Tag: Sogroya
-
Canada Welcomes Sogroya: The First Once-Weekly Growth Hormone Therapy for All Ages
Canada launches Sogroya: a pioneering once-weekly growth hormone treatment Canada has officially announced the commercialization of Sogroya® (somapacitan injection), marking a significant advancement in the treatment of growth hormone deficiency (GHD). As the first-and-only once-weekly growth hormone (GH) therapy indicated for both pediatric and adult patients, Sogroya® offers a convenient alternative to daily injections for…
-
Sogroya Arrives in Canada: First Weekly GH Therapy for GHD
Sogroya® hits the Canadian market as a once-weekly growth hormone option Novo Nordisk has announced that Sogroya® (somapacitan injection) is now commercially available in Canada, marking a new milestone for growth hormone deficiency (GHD) treatment. Sogroya® is indicated for the long-term management of pediatric patients with growth failure due to inadequate endogenous growth hormone and…
-
Canada Welcomes Sogroya: The First Weekly Growth Hormone Therapy for GHD
Canada Launches Sogroya as the First Weekly Growth Hormone Therapy for GHD Canada has welcomed Sogroya® (somapacitan injection) as a new, once-weekly option for children and adults living with growth hormone deficiency (GHD). This landmark approval marks the first and only regimen of its kind that reduces the frequency of injections while delivering effective growth…